Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

Risk for recurrent venous thromboembolism reduced for patients with isolated distal DVT receiving six additional weeks of rivaroxaban
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news